JP2021531234A5 - - Google Patents

Info

Publication number
JP2021531234A5
JP2021531234A5 JP2020555323A JP2020555323A JP2021531234A5 JP 2021531234 A5 JP2021531234 A5 JP 2021531234A5 JP 2020555323 A JP2020555323 A JP 2020555323A JP 2020555323 A JP2020555323 A JP 2020555323A JP 2021531234 A5 JP2021531234 A5 JP 2021531234A5
Authority
JP
Japan
Prior art keywords
compound according
substituted
alkyl
heterocyclyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020555323A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021531234A (ja
JP7365358B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/027141 external-priority patent/WO2019200202A1/en
Publication of JP2021531234A publication Critical patent/JP2021531234A/ja
Publication of JP2021531234A5 publication Critical patent/JP2021531234A5/ja
Priority to JP2023174330A priority Critical patent/JP7700193B2/ja
Application granted granted Critical
Publication of JP7365358B2 publication Critical patent/JP7365358B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020555323A 2018-04-12 2019-04-12 ヒトインテグリンα4β7のアンタゴニスト Active JP7365358B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023174330A JP7700193B2 (ja) 2018-04-12 2023-10-06 ヒトインテグリンα4β7のアンタゴニスト

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862656742P 2018-04-12 2018-04-12
US62/656,742 2018-04-12
PCT/US2019/027141 WO2019200202A1 (en) 2018-04-12 2019-04-12 Antagonists of human integrin (alpha4)(beta7)

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023174330A Division JP7700193B2 (ja) 2018-04-12 2023-10-06 ヒトインテグリンα4β7のアンタゴニスト

Publications (3)

Publication Number Publication Date
JP2021531234A JP2021531234A (ja) 2021-11-18
JP2021531234A5 true JP2021531234A5 (cg-RX-API-DMAC7.html) 2022-04-20
JP7365358B2 JP7365358B2 (ja) 2023-10-19

Family

ID=68161020

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020555323A Active JP7365358B2 (ja) 2018-04-12 2019-04-12 ヒトインテグリンα4β7のアンタゴニスト
JP2023174330A Active JP7700193B2 (ja) 2018-04-12 2023-10-06 ヒトインテグリンα4β7のアンタゴニスト

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023174330A Active JP7700193B2 (ja) 2018-04-12 2023-10-06 ヒトインテグリンα4β7のアンタゴニスト

Country Status (9)

Country Link
US (4) US10759756B2 (cg-RX-API-DMAC7.html)
EP (1) EP3773573B1 (cg-RX-API-DMAC7.html)
JP (2) JP7365358B2 (cg-RX-API-DMAC7.html)
CN (1) CN112312910A (cg-RX-API-DMAC7.html)
AR (1) AR114489A1 (cg-RX-API-DMAC7.html)
ES (1) ES3070453T3 (cg-RX-API-DMAC7.html)
MA (1) MA52249A (cg-RX-API-DMAC7.html)
TW (2) TW202528300A (cg-RX-API-DMAC7.html)
WO (1) WO2019200202A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202528300A (zh) 2018-04-12 2025-07-16 美商莫菲克醫療股份有限公司 人類整合素α4β7拮抗劑
WO2020092394A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
WO2020092401A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. COMPOUNDS FOR INHIBITION OF ALPHA 4β7 INTEGRIN
ES2987796T3 (es) 2018-10-30 2024-11-18 Gilead Sciences Inc Derivados de N-benzoil-fenilalanina como inhibidores de la integrina alfa4beta7 para el tratamiento de enfermedades inflamatorias
DK3873884T3 (da) 2018-10-30 2025-02-17 Gilead Sciences Inc 3-(quinolin-8-yl)-1,4-dihydropyrido[3,4-d]pyrimidin-2,4-dion-derivater som alpha4beta7-integrinhæmmere til behandling af inflammatoriske sygdomme
AU2020329207B2 (en) 2019-08-14 2024-02-29 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
BR112022007284A2 (pt) * 2019-10-16 2022-07-05 Morphic Therapeutic Inc Inibição de integrina humana alpha-4 beta-7
AU2021381396A1 (en) * 2020-11-20 2023-06-22 Denali Therapeutics Inc. Compounds, compositions, and methods
US20250195485A1 (en) * 2021-12-27 2025-06-19 Xizang Haisco Pharmaceutical Co., Ltd. Propionic acid derivative and medical use thereof
EP4585587A1 (en) * 2022-09-09 2025-07-16 Xizang Haisco Pharmaceutical Co., Ltd. Propionic acid derivative and use thereof in medicine
CN120500479A (zh) * 2022-12-22 2025-08-15 新特拉有限公司 α4β7整联蛋白拮抗剂及其用途
CN120957974A (zh) * 2023-02-21 2025-11-14 希四克斯探索有限公司 大环α4β7整合素抑制剂
WO2025026955A1 (en) * 2023-07-28 2025-02-06 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
TW202515852A (zh) * 2023-09-15 2025-04-16 美商莫菲克醫療股份有限公司 抑制人類整合素α4β7
US12684500B2 (en) 2024-01-17 2026-07-14 T-Mobile Usa, Inc. Dynamic scheduling request framework for HP UE SAR reduction
WO2025176107A1 (zh) * 2024-02-20 2025-08-28 西藏海思科制药有限公司 一种吡啶酮衍生物及其在医药上的应用
WO2026138905A1 (zh) * 2024-12-24 2026-07-02 湖北生物医药产业技术研究院有限公司 作为整合素α4β7拮抗剂的噻吩类化合物及其用途
WO2026138844A1 (zh) * 2024-12-24 2026-07-02 湖北生物医药产业技术研究院有限公司 酰胺类化合物及其作为整合素α4β7拮抗剂的用途

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
DE69425431T2 (de) * 1993-03-31 2001-02-08 G.D. Searle & Co., Chicago 1-amdinophenyl-pyrrolidone/piperidinone als blutblättchen-aggregations inhibitoren
DE4427979A1 (de) * 1993-11-15 1996-02-15 Cassella Ag Substituierte 5-Ring-Heterocyclen, ihre Herstellung und ihre Verwendung
CA2174838A1 (en) 1993-11-24 1995-06-01 John Wityak Novel isoxazoline and isoxazole fibrinogen receptor antagonists
US5849736A (en) * 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
DE19622489A1 (de) 1996-06-05 1997-12-11 Hoechst Ag Salze des 3-(2-(4-(4-(Amino-imino-methyl)-phenyl)-4- methyl-2,5-dioxo-imidazolidin-1-yl)-acetylamino)-3- phenyl-propionsäure-ethylesters
US5981546A (en) * 1996-08-29 1999-11-09 Merck & Co., Inc. Integrin antagonists
CA2268381A1 (en) 1996-10-11 1998-04-23 Cor Therapeutics, Inc. Selective factor xa inhibitors
WO1998016524A1 (en) 1996-10-11 1998-04-23 Cor Therapeutics, Inc. HETEROCYCLIC DERIVATIVES AS FACTOR Xa INHIBITORS
DE19751251A1 (de) * 1997-11-19 1999-05-20 Hoechst Marion Roussel De Gmbh Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate
US6645939B1 (en) 1997-11-24 2003-11-11 Merck & Co., Inc. Substituted β-alanine derivatives as cell adhesion inhibitors
MY153569A (en) 1998-01-20 2015-02-27 Mitsubishi Tanabe Pharma Corp Inhibitors of ?4 mediated cell adhesion
DE19821483A1 (de) * 1998-05-14 1999-11-18 Hoechst Marion Roussel De Gmbh Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
WO2000000481A1 (en) 1998-06-29 2000-01-06 Du Pont Pharmaceuticals Company Cyclic carbamates and isoxazolidines as iib/iiia antagonists
GB9826174D0 (en) * 1998-11-30 1999-01-20 Celltech Therapeutics Ltd Chemical compounds
SK288186B6 (sk) 1999-05-07 2014-05-06 Encysive Pharmaceuticals, Inc. Deriváty kyseliny propiónovej, ktoré inhibujú väzbu integrínov na ich receptory, farmaceutické kompozície s ich obsahom a ich použitie
US6723711B2 (en) * 1999-05-07 2004-04-20 Texas Biotechnology Corporation Propanoic acid derivatives that inhibit the binding of integrins to their receptors
US6972296B2 (en) 1999-05-07 2005-12-06 Encysive Pharmaceuticals Inc. Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
EP1214292B1 (en) 1999-09-24 2007-06-13 Genentech, Inc. Tyrosine derivatives
DE10041423A1 (de) 2000-08-23 2002-03-07 Merck Patent Gmbh Biphenylderivate
DE10111876A1 (de) * 2001-03-10 2002-09-19 Aventis Pharma Gmbh Bis(trifluormethyl)hydantoine als Zwischenprodukte für pharmazeutische Wirkstoffe
DE10154280A1 (de) 2001-11-05 2003-05-15 Wilex Ag Antagonisten für alpha¶4¶-Integrine
KR20040105740A (ko) 2002-02-25 2004-12-16 엘란 파마슈티칼스, 인크. 염증 치료제의 투여 방법
ES2377979T3 (es) 2004-09-03 2012-04-03 Genentech, Inc. Antagonistas anti-beta7 humanizados y utilizaciones para los mismos
ES2387317T3 (es) 2005-03-03 2012-09-20 Seedlings Life Science Ventures, Llc. Procedimiento de control de riesgos de pacientes en tratamiento con natalizumab
WO2006126529A1 (ja) 2005-05-25 2006-11-30 Shionogi & Co., Ltd. 6,7-不飽和-7-カルバモイル置換モルヒナン誘導体
CA2610800A1 (en) 2005-06-09 2006-12-14 Ucb Pharma, S.A. 2,6 quinolinyl derivatives, processes for preparing them and their use as medicament
HUE047230T2 (hu) 2006-02-28 2020-04-28 Biogen Ma Inc Gyulladásos és autoimmun betegségek natalizumabbal való kezelésének módszerei
US20100272680A1 (en) 2009-02-09 2010-10-28 Subramanian Baskaran Piperidinyl Cyclic Amido Antiviral Agents
MX2013011130A (es) 2011-03-31 2013-10-30 Genentech Inc Metodos de administracion de antagonistas de integrina beta7.
KR101850591B1 (ko) 2012-10-05 2018-04-19 제넨테크, 인크. 염증성 장 질환의 진단 및 치료 방법
JP7054990B2 (ja) 2014-03-27 2022-04-15 ジェネンテック, インコーポレイテッド 炎症性腸疾患の診断及び治療のための方法
CN105658641B (zh) 2014-07-25 2018-04-17 江苏恒瑞医药股份有限公司 氮茚‑酰胺类衍生物、其制备方法及其在医药上的应用
EP3978530A1 (en) 2015-02-26 2022-04-06 F. Hoffmann-La Roche AG Integrin beta7 antagonists and methods of treating crohn's disease
US10246451B2 (en) 2017-04-26 2019-04-02 Aviara Pharmaceuticals, Inc. Propionic acid derivatives and methods of use thereof
TW202528300A (zh) * 2018-04-12 2025-07-16 美商莫菲克醫療股份有限公司 人類整合素α4β7拮抗劑
DK3873884T3 (da) 2018-10-30 2025-02-17 Gilead Sciences Inc 3-(quinolin-8-yl)-1,4-dihydropyrido[3,4-d]pyrimidin-2,4-dion-derivater som alpha4beta7-integrinhæmmere til behandling af inflammatoriske sygdomme
ES2987796T3 (es) 2018-10-30 2024-11-18 Gilead Sciences Inc Derivados de N-benzoil-fenilalanina como inhibidores de la integrina alfa4beta7 para el tratamiento de enfermedades inflamatorias
WO2020092394A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
WO2020092401A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. COMPOUNDS FOR INHIBITION OF ALPHA 4β7 INTEGRIN
BR112022007284A2 (pt) 2019-10-16 2022-07-05 Morphic Therapeutic Inc Inibição de integrina humana alpha-4 beta-7

Similar Documents

Publication Publication Date Title
CN113365997A (zh) 作为c-Met抑制剂的含嘧啶基团的三并环类化合物
JP2022538917A5 (cg-RX-API-DMAC7.html)
JP2024514837A5 (cg-RX-API-DMAC7.html)
IL321451A (en) Compositions and methods of modulating short-chain dehydrogenase activity
JP2017518959A5 (cg-RX-API-DMAC7.html)
JP2018522012A5 (cg-RX-API-DMAC7.html)
JP2020527175A5 (cg-RX-API-DMAC7.html)
JP2019518766A5 (cg-RX-API-DMAC7.html)
RU2012108629A (ru) Фенилэтинильные производные в качестве ингибиторов вируса гепатита с
JP2016534134A5 (cg-RX-API-DMAC7.html)
JP2014508811A5 (cg-RX-API-DMAC7.html)
EA035500B1 (ru) Производные сульфамоилтиофенамида и их применение в качестве медикаментов для лечения гепатита b
IL287159B1 (en) Small molecules agonists for FXR (farnesoid X receptor) and method for their preparation and use
JP2011520969A5 (cg-RX-API-DMAC7.html)
JP2024518555A5 (cg-RX-API-DMAC7.html)
EA201600241A1 (ru) Замещенные (2r,3r,5r)-3-гидрокси-(5-пиримидин-1-ил)тетрагидрофуран-2-илметил арил фосфорамидаты
JP2018504441A5 (cg-RX-API-DMAC7.html)
JP2021530560A5 (cg-RX-API-DMAC7.html)
JP2020521739A5 (cg-RX-API-DMAC7.html)
JP2021533206A5 (cg-RX-API-DMAC7.html)
JP2015504075A5 (cg-RX-API-DMAC7.html)
JP2022533939A5 (cg-RX-API-DMAC7.html)
RU2019131147A (ru) Новые хиназолиноновые производные, ингибирующие pi3k, и содержащая их фармацевтическая композиция
JP2019533007A5 (cg-RX-API-DMAC7.html)
JP2017513852A5 (cg-RX-API-DMAC7.html)